FDA approved device for facial skin tightening

Trial ID:
IRB-22-7948
E. Victor Ross, M.D.
This study will evaluate the safety and effectiveness of the FDA approved UltraClear laser device for the improvement of skin appearance and skin texture. The cosmetic device uses a skin peeling process to improve skin properties such as softness, elasticity, and appearance. Participation in this study requires attending 5-6 study visits over a 7–8-month period. Study visits will take place at the Scripps Clinic Carmel Valley.

Inclusion Criteria

Patients must:
  • - Be between 18 and 75 years of age
  • - Have clinically identifiable photodamage on facial skin, neck, or chest
  • - Be willing and able to comply with all follow-up requirements
  • - Meet all other eligibility requirements

Exclusion Criteria

Patients must not:
  • - Have active localized or systemic infections
  • - Have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease, atrophic dermatitis, or immunologic abnormalities such as vitiligo
  • - Be currently taking Accutane
  • - Have a known allergy to lidocaine (numbing cream)
  • - Have used topical steroids or retinoids within the last 3 months on treatment surfaces
  • - Have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia
  • - Use cosmeceutical agents or topical agents during the course of the study, except as directed by study investigators
  • - Be pregnant
  • - Be exposed to excessive sun burn over the past 2 months

Additional Info

  • The UltraClear Laser system is intended to improve photodamage by reducing fine lines, wrinkles, and acne scars and improving skin tone, appearance and texture.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org